Evidence map›Paper›PMID 35535075›Full record

ReviewJournal of clinical and experimental hepatology

Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.

Dibya L Praharaj, Anil C Anand

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases.Journal of the American Society of Nephrology : JASN · 2025
    Article
  8. [Effects of ascites grading and the application of non-selective beta-blockers on the 1-year prognosis of acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Evidence-based hyponatremia management in liver disease.Clinical and molecular hepatology · 2023
    Review
  14. Review
  15. Management of Portal Hypertension.Journal of clinical and experimental hepatology
    Review
  16. Overview of Complications in Cirrhosis.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dibya L PraharajDepartment of Gastroenterology and Hepatology, Kalinga Institute of Medical Science, Bhubaneswar, Odisha, India.
Anil C AnandDepartment of Gastroenterology and Hepatology, Kalinga Institute of Medical Science, Bhubaneswar, Odisha, India.
All India Institute of Medical Sciences Bhubaneswar · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyponatremia is the most common electrolyte abnormality in patients with decompensated cirrhosis on Liver Transplantation (LT) waiting list. Most of these patients have dilutional or hypervolemic hyponatremia secondary to splanchnic vasodilatation. Excessive secretion of the antidiuretic hormone also plays an important role. Hypervolemic hyponatremia is commonly associated with refractory ascites, spontaneous bacterial peritonitis, and hepatic encephalopathy. Although uncommon, the use of diuretics and laxatives can cause hypovolemic hyponatremia that is characterized by the striking absence of ascites or pedal edema. Clinical features are often nonspecific and depend on the acuity of onset rather than the absolute value of serum sodium. Symptoms may be subtle, including nausea, lethargy, weakness, or anorexia. However, rarely patients may present with confusion, seizures, psychosis, or coma. Treatment includes discontinuation of diuretics, beta-blockers, and albumin infusion. Hypertonic saline (3%) infusion may be used in patients with very low serum sodium (<110 mmol/L) or when patients present with seizures or coma. Short-term use of Vasopressin (V

Indexed as

ACE, angiotensin-converting enzymeACLF, acute-on-chronic liver failureACTH, adrenocorticotropic hormoneADHADH, antidiuretic hormoneadvanced cirrhosisAKI, acute kidney injuryalbuminAVP, arginine vasopressinCLIF, chronic liver failureCNS, central nervous systemCTP, Child-Turcotte-PughCVVHD, continuous venovenous hemofiltrationDAMP, damage-associated molecular patternsEABV, effective arterial blood volumeFENa, fractional excretion of sodiumHE, hepatic encephalopathyHRS, hepatorenal syndromehyponatremialiver transplantationLT, liver transplantationLVP, large volume paracentesisMAP, mean arterial pressureMELD, model of end-stage liver diseaseNO, nitric oxideNSBB, nonselective beta-blockersPAMP, pathogen-associated molecular patternsPICD, paracentesis-induced circulatory dysfunctionPPCD, post-paracentesis circulatory dysfunctionPRA, plasma renin activityRAAS, renin-angiotensin-aldosterone-systemRAI, relative adrenal insufficiencyRA, refractory ascitesRBF, renal blood flowSBP, spontaneous bacterial peritonitisSIADH, syndrome of inappropriate ADH secretionSMT, standard medical treatmentsNa, serum sodiumSNS, sympathetic nervous systemTBW, total body waterTIPS, transjugular intrahepatic portosystemic shunt

Identifiers

PMID35535075
PMCPMC9077240
OpenAlexW3199358835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.